The effect of an interventional program on adherence to the American Academy of Pediatrics guidelines for palivizumab prophylaxis

被引:10
作者
Afghani, Behnoosh [1 ]
Ngo, Thienkim
Leu, Szu-Yun
Wu, Fu L.
Cecilio, Maricel
Aron-Johnson, Pamela
Zeitany, Raja
Sills, Jack
Amin, Alpesh
机构
[1] Univ Calif Irvine, Hospitalist Program, Dept Pediat, Irvine, CA USA
[2] Univ Calif Irvine, Dept Med, Irvine, CA USA
关键词
palivizumab; intervention; respiratory syncytial virus; adherence; American Academy of Pediatrics;
D O I
10.1097/01.inf.0000243164.47048.4b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the effect of an interventional program designed to improve adherence to American Academy of Pediatrics (AAP) guidelines for palivizumab prophylaxis. Methods: The study was carried out at the Children's Hospital, University of California, Irvine Medical Center and its affiliated clinics. An interventional program focusing on education of health care workers on AAP guidelines, updating health care providers about respiratory syncytial virus (RSV) activity, as well as designating a single clinic with effective screening of referrals for administration of palivizumab, was implemented during the summer of 2004. The medical records of infants who had received at least 1 dose of palivizumab or were eligible to receive palivizumab during the 2003-2004 and the 2004-2005 RSV seasons at the University of California, Irvine Medical Center were reviewed. The proportion of patients who received injections according to AAP guidelines was compared. Results: After the intervention, the proportion of patients who received palivizumab injections according to AAP recommendations increased from 39% to 61% (P < 0.0001). The program decreased the proportion of unnecessary injections significantly (140/525, or 27%, in 2003-2004 to 33/323, or 10%, in 2004-2005; P < 0.0001) but did not change the proportion of missing injections. The program resulted in a significant drop (14% to 2%; P < 0.0001) in proportion of palivizumab injections that were given too late, when RSV activity had subsided. RSV hospitalization rates did not change as a result of the intervention. Conclusions: Our interventional program improved adherence to AAP guidelines mainly by decreasing the unnecessary palivizumab injections.
引用
收藏
页码:1019 / 1024
页数:6
相关论文
共 16 条
  • [1] Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections
    Abramson, JS
    Baker, CJ
    Baltimore, RS
    Bocchini, JA
    Long, SS
    McMillan, JA
    Meissner, HC
    Powell, KR
    Prober, CG
    Rennels, MB
    Saari, TN
    Weiner, LB
    Blackmon, L
    Batton, DG
    Bell, EF
    Denson, SE
    Engle, WA
    Kanto, WP
    Martin, GI
    Stark, AR
    [J]. PEDIATRICS, 2003, 112 (06) : 1447 - 1452
  • [2] Abramson JS, 2003, PEDIATRICS, V112, P1442
  • [3] Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
    Boyce, TG
    Mellen, BG
    Mitchel, EF
    Wright, PF
    Griffin, MR
    [J]. JOURNAL OF PEDIATRICS, 2000, 137 (06) : 865 - 870
  • [4] *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P1159
  • [5] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
    Feltes, TF
    Cabalka, AK
    Meissner, C
    Piazza, FM
    Carlin, DA
    Top, FH
    Connor, EM
    Sondheimer, HM
    [J]. JOURNAL OF PEDIATRICS, 2003, 143 (04) : 532 - 540
  • [6] Decreasing antibiotic use in ambulatory practice - Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults
    Gonzales, R
    Steiner, JF
    Lum, A
    Barrett, PH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (16): : 1512 - 1519
  • [7] Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study
    Henderson, J
    Hilliard, TN
    Sherriff, A
    Stalker, D
    Shammari, NA
    Thomas, HM
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2005, 16 (05) : 386 - 392
  • [8] Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants
    Joffe, S
    Ray, GT
    Escobar, GJ
    Black, SB
    Lieu, TA
    [J]. PEDIATRICS, 1999, 104 (03) : 419 - 427
  • [9] Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants - A systematic review
    Kamal-Bahl, S
    Doshi, J
    Campbell, J
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2002, 156 (10): : 1034 - 1041
  • [10] Impact of palivizumab on expected costs of respiratory syncytial virus infection int preterm infants: Potential for savings
    Marchetti, A
    Lau, W
    Magar, R
    Wang, LP
    Devercelli, G
    [J]. CLINICAL THERAPEUTICS, 1999, 21 (04) : 752 - 766